Skip to main content
    C

    Citius Pharmaceuticals Inc (CTXR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.53
    -0.01 (-1.40%)

    Market Cap: $14.69M

    Last updated: Nov 17, 2026 at 11:00 AM ET

    Citius Pharmaceuticals Inc (CTXR) Financials: Revenue, Profit and Cash Flow

    Updated Aug 14, 2026. Financial statements from company filings, amounts in US dollars.

    Citius Pharmaceuticals reported revenue of $0 for the fiscal year ended Sep 30, 2025. That year, net income was -$39.74M, operating cash flow was -$26.55M and free cash flow was -$26.55M. The quarter ended Jun 30, 2026 had revenue of $1.49M and net income of -$11.92M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Sep 2025, with an operating loss of $38.53M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Sep 2025$0N/AN/AN/AN/A
    Sep 2024$0N/AN/AN/AN/A
    Sep 2023$0N/AN/AN/AN/A
    Sep 2022$0N/AN/AN/AN/A
    Sep 2021$0N/AN/AN/AN/A
    Sep 2020$0N/AN/AN/AN/A
    Sep 2019$0N/AN/AN/AN/A
    Sep 2018$0N/AN/AN/AN/A
    Sep 2017$0N/AN/AN/AN/A
    Sep 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Sep 2016 to Sep 2025

    Income Statement

    In the fiscal year ended Sep 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Research and development$9.16M$11.91M$14.82M$17.66M$12.24M$8.81M$8.60M$6.56M$2.94M$2.93M
    Operating income-$38.53M-$42.00M-$36.73M-$33.32M-$23.53M-$17.71M-$15.60M-$13.79M-$9.99M-$7.45M
    Net income-$39.74M-$39.43M-$32.54M-$33.64M-$23.05M-$17.55M-$15.56M-$12.54M-$10.38M-$8.30M
    EBITDA-$38.31M-$39.40M-$36.54M-$33.14M-$23.31M-$17.45M-$15.60M-$12.97M-$9.53MN/A
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$1.49M$1.67M$3.94M$0$0$0$0$155.93K$0$0$0$0
    Gross profit$1.00M$1.34M$3.15M-$62.04K$0$0$0-$53.69K$0$0$0-$49.97K
    Operating income-$11.73M-$32.19M-$9.02M-$8.44M-$8.79M-$11.26M-$10.04M-$11.05M-$10.63M-$10.97M-$9.34M-$10.12M
    Net income-$11.92M-$28.11M-$9.39M-$8.74M-$9.20M-$11.51M-$10.28M-$11.08M-$10.57M-$8.54M-$9.23M-$9.94M
    Last 12 quarters

    Balance Sheet

    As of Sep 2025, cash and equivalents exceeded total debt of $1.00M by $3.25M.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Total assets$130.94M$116.65M$103.61M$114.00M$142.43M$43.77M$36.75M$31.05M$24.42M$21.95M
    Current assets$27.93M$14.22M$34.37M$44.56M$72.81M$13.98M$7.94M$10.06M$3.42M$892.84K
    Cash and equivalents$4.25M$3.25M$26.48M$41.71M$70.07M$13.86M$7.89M$9.18M$3.20M$294.35K
    Total liabilities$53.41M$42.55M$12.18M$10.57M$9.65M$10.10M$9.59M$3.18M$2.47M$5.18M
    Short-term debt$1.00M$0$436.76K$393.98K$354.47K$172.97K$172.97K$172.97K$172.97K$672.97K
    Long-term debt$0N/AN/AN/AN/A$164.58K$0N/AN/AN/A
    Shareholder equity$67.55M$70.08M$90.83M$102.83M$132.18M$33.67M$27.15M$27.87M$21.95M$16.77M
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$142.26M$132.54M$140.39M$130.94M$127.68M$121.48M$120.70M$116.65M$97.09M$90.71M$97.40M$103.61M
    Total liabilities$66.35M$63.46M$46.92M$53.41M$60.12M$57.91M$51.78M$42.55M$10.81M$10.74M$12.07M$12.18M
    Cash and equivalents$17.01M$4.59M$7.72M$4.25M$6.09M$26.41K$1.10M$3.25M$17.91M$12.56M$20.35M$26.48M
    Shareholder equity$66.61M$61.54M$79.96M$67.55M$65.06M$60.66M$65.41M$70.08M$85.68M$79.37M$84.73M$90.83M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Sep 2025.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Operating cash flow-$26.55M-$28.20M-$29.06M-$28.36M-$24.25M-$16.93M-$12.44M-$11.32M-$7.97M-$5.90M
    Capital expenditures$0$0$2$0$40.01M$1.83K$0$0$2.13K$0
    Free cash flow-$26.55M-$28.20M-$29.06M-$28.36M-$64.26M-$16.93M-$12.44M-$11.32M-$7.97M-$5.90M
    Dividends paid$0$3.83M$0N/AN/AN/AN/AN/AN/AN/A
    Investing cash flow-$5.75M-$5.00M$0$0-$40.01M-$1.83K$0$0-$2.13K$255.75K
    Financing cash flow$33.30M$9.97M$13.83M$0$120.47M$22.90M$11.15M$17.30M$10.88M$5.26M
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$8.68M-$1.30M-$13.01M-$11.88M-$5.41M-$4.54M-$4.73M-$5.91M-$8.37M-$7.79M-$6.14M-$6.80M
    Capital expendituresN/A$0$0$4$0$4$0$0$4$0$0$0
    Free cash flowN/A-$1.30M-$13.01M-$11.88M-$5.41M-$4.54M-$4.73M-$5.91M-$8.37M-$7.79M-$6.14M-$6.80M
    Last 12 quarters

    Frequently Asked Questions About CTXR

    What is Citius Pharmaceuticals' annual revenue?

    Citius Pharmaceuticals reported revenue of $0 for the fiscal year ended Sep 30, 2025.

    Is Citius Pharmaceuticals profitable?

    No. Citius Pharmaceuticals reported net income of -$39.74M for the fiscal year ended Sep 30, 2025.

    How much free cash flow does CTXR generate?

    For the fiscal year ended Sep 30, 2025, operating cash flow of -$26.55M minus capital expenditures of $0 produced free cash flow of -$26.55M.

    How much debt does Citius Pharmaceuticals have?

    The balance sheet dated Sep 30, 2025 reported long-term debt of $0, short-term debt of $1.00M and cash and equivalents of $4.25M.